Department of Biochemical and Chemical Engineering, Laboratory of Thermodynamics, TU Dortmund University, Emil-Figge-Strasse 70, D-44227 Dortmund, Germany.
AbbVie Deutschland GmbH & Co. KG, Global Pharmaceutical R&D, Knollstraße, D-67061 Ludwigshafen am Rhein, Germany.
Mol Pharm. 2020 Jul 6;17(7):2721-2733. doi: 10.1021/acs.molpharmaceut.0c00418. Epub 2020 Jun 16.
Understanding and prevention of unwanted changes of a pharmaceutical formulation during the production process is part of the critical requirements for the successful approval of a new drug product. Polymer-based formulations, so-called amorphous solid dispersions (ASDs), are often produced via solvent-based processes. In such processes, active pharmaceutical ingredients (APIs) and polymers are first dissolved in a solvent or solvent mixture, then the solvent is evaporated, for example, via spray drying or rotary evaporation. During the drying step, unwanted liquid-liquid phase separation may occur, leading to polymer-rich and API-rich regions with crystallization potential, and thus, heterogeneities and a two-phasic system in the final ASD. Phase separation in ASDs may impact their bioperformance because of the locally higher degree of API supersaturation. Although it is known that the choice of the solvent plays an important role in the formation of heterogeneities, solvent-impact on ASD drying and eventual product quality is often neglected in the process design. This study aims to investigate for the first time the phase behavior and drying process of API/polymer/solvents systems from a thermodynamic perspective. Unwanted phase changes during the drying process of the ASD containing hydroxypropyl methylcellulose acetate succinate and naproxen prepared from acetone/water or ethanol/water solvent mixtures were predicted using the thermodynamic model PC-SAFT. The predicted phase behavior and drying curves were successfully validated by confocal Raman spectroscopy.
理解和预防药物制剂在生产过程中发生不需要的变化是成功批准新药产品的关键要求之一。基于聚合物的制剂,即所谓的无定形固体分散体(ASD),通常通过溶剂型工艺生产。在这样的工艺中,活性药物成分(APIs)和聚合物首先溶解在溶剂或溶剂混合物中,然后蒸发溶剂,例如通过喷雾干燥或旋转蒸发。在干燥步骤中,可能会发生不需要的液-液相分离,导致具有结晶潜力的聚合物富区和 API 富区,从而在最终的 ASD 中形成不均匀性和两相体系。ASD 中的相分离可能会影响其生物性能,因为局部 API 过饱和度更高。尽管已知溶剂的选择对不均匀性的形成起着重要作用,但在工艺设计中,溶剂对 ASD 干燥和最终产品质量的影响往往被忽视。本研究首次从热力学角度研究 API/聚合物/溶剂系统的相行为和干燥过程。使用热力学模型 PC-SAFT 预测了含有羟丙基甲基纤维素醋酸琥珀酸酯和萘普生的 ASD 在丙酮/水或乙醇/水溶剂混合物中的干燥过程中不需要的相变化。通过共聚焦拉曼光谱成功验证了预测的相行为和干燥曲线。